1. Uh Y, Hwang GY, Jang IH, Kwon O, Kim HY, Yoon KJ. Antimicrobial susceptibility patterns and macrolide resistance genes of β-hemolytic viridans group streptococci in a tertiary Korean hospital. J Korean Med Sci. 2007; 22:791–794. PMID:
17982224.
Article
2. Gillespie SH. Failure of penicillin in
Streptococcus pyogenes pharyngeal infection. Lancet. 1998; 352:1954–1956. PMID:
9872242.
3. Schuchat A. Group B streptococcal disease: from trials and tribulations to triumph and trepidation. Clin Infect Dis. 2001; 33:751–756. PMID:
11512078.
Article
4. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis. 2002; 35:113–125. PMID:
12087516.
Article
5. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial surveillance program (1997-2000). Diagn Microbiol Infect Dis. 2002; 43:157–162. PMID:
12088624.
Article
6. Jones RN, Sader HS. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly? Diagn Microbiol Infect Dis. 2006; 55:351–356. PMID:
16765555.
Article
7. Hindler JF, Patel JB. Murray PR, Baron EJ, editors. Susceptibility test methods: fastidious bacteria. Manual of clinical microbiology. 2007. 9th ed. Washington, DC: American Society for Microbiology Press;p. 1193–1213.
8. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 1996; 40:891–894. PMID:
8849246.
Article
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement, M100-S20. 2010. Wayne, PA: Clinical and Laboratory Standards Institute.
10. Barenfanger J, Short MA, Groesch AA. Improved antimicrobial interventions have benefits. J Clin Microbiol. 2001; 39:2823–2828. PMID:
11473998.
Article
11. Kerremans JJ, Verboom P, Stijnen T, Hakkaart-van Roijen L, Goessens W, Verbrugh HA, et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother. 2008; 61:428–435. PMID:
18156278.
Article
12. Guthrie LL, Banks S, Setiawan W, Waites KB. Comparison of MicroScan MICroSTREP, PASCO, and Sensititre MIC panels for determining antimicrobial susceptibilities of
Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1999; 33:267–273. PMID:
10212754.
13. Mittman SA, Huard RC, Della-Latta P, Whittier S. Comparison of BD phoenix to Vitek 2, MicroScan MICroSTREP, and Etest for antimicrobial susceptibility testing of
Streptococcus pneumoniae. J Clin Microbiol. 2009; 47:3557–3561. PMID:
19741088.
14. Jorgensen JH, McElmeel ML, Crawford SA. Evaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected
Streptococcus pneumoniae challenge strains and recent clinical isolates. J Clin Microbiol. 1998; 36:788–791. PMID:
9508313.
15. Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. guidance for industry and FDA. 2007. Rockville, MD: Food and Drug Administration.